EP1572067A4 - Conjugues et compositions pour administration cellulaire - Google Patents

Conjugues et compositions pour administration cellulaire

Info

Publication number
EP1572067A4
EP1572067A4 EP02746413A EP02746413A EP1572067A4 EP 1572067 A4 EP1572067 A4 EP 1572067A4 EP 02746413 A EP02746413 A EP 02746413A EP 02746413 A EP02746413 A EP 02746413A EP 1572067 A4 EP1572067 A4 EP 1572067A4
Authority
EP
European Patent Office
Prior art keywords
conjugates
compositions
cell delivery
delivery
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02746413A
Other languages
German (de)
English (en)
Other versions
EP1572067A2 (fr
Inventor
Leonid Beigelman
Jasenka Matulic-Adamic
Chandra Vargeese
Alexander Karpeisky
Lawrence Blatt
Christopher Shaffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirna Therapeutics Inc
Original Assignee
Sirna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirna Therapeutics Inc filed Critical Sirna Therapeutics Inc
Priority to EP17000268.7A priority Critical patent/EP3231445A1/fr
Priority to EP11184529.3A priority patent/EP2415486B1/fr
Publication of EP1572067A2 publication Critical patent/EP1572067A2/fr
Publication of EP1572067A4 publication Critical patent/EP1572067A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
EP02746413A 2001-05-18 2002-05-17 Conjugues et compositions pour administration cellulaire Withdrawn EP1572067A4 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP17000268.7A EP3231445A1 (fr) 2001-05-18 2002-05-17 Conjugués et compositions pour la fourniture cellulaire
EP11184529.3A EP2415486B1 (fr) 2001-05-18 2002-05-17 Conjugués et compositions pour la fourniture cellulaire

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US29221701P 2001-05-18 2001-05-18
US292217P 2001-05-18
US30688301P 2001-07-20 2001-07-20
US306883P 2001-07-20
US31186501P 2001-08-13 2001-08-13
US311865P 2001-08-13
US36201602P 2002-03-06 2002-03-06
US362016P 2002-03-06
PCT/US2002/015876 WO2002094185A2 (fr) 2001-05-18 2002-05-17 Conjugues et compositions pour administration cellulaire

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP17000268.7A Division EP3231445A1 (fr) 2001-05-18 2002-05-17 Conjugués et compositions pour la fourniture cellulaire
EP11184529.3A Division EP2415486B1 (fr) 2001-05-18 2002-05-17 Conjugués et compositions pour la fourniture cellulaire

Publications (2)

Publication Number Publication Date
EP1572067A2 EP1572067A2 (fr) 2005-09-14
EP1572067A4 true EP1572067A4 (fr) 2009-05-13

Family

ID=27501563

Family Applications (3)

Application Number Title Priority Date Filing Date
EP02746413A Withdrawn EP1572067A4 (fr) 2001-05-18 2002-05-17 Conjugues et compositions pour administration cellulaire
EP17000268.7A Ceased EP3231445A1 (fr) 2001-05-18 2002-05-17 Conjugués et compositions pour la fourniture cellulaire
EP11184529.3A Expired - Lifetime EP2415486B1 (fr) 2001-05-18 2002-05-17 Conjugués et compositions pour la fourniture cellulaire

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP17000268.7A Ceased EP3231445A1 (fr) 2001-05-18 2002-05-17 Conjugués et compositions pour la fourniture cellulaire
EP11184529.3A Expired - Lifetime EP2415486B1 (fr) 2001-05-18 2002-05-17 Conjugués et compositions pour la fourniture cellulaire

Country Status (6)

Country Link
EP (3) EP1572067A4 (fr)
JP (2) JP4358521B2 (fr)
AU (2) AU2002316135B9 (fr)
CA (1) CA2447161A1 (fr)
HK (1) HK1244675A1 (fr)
WO (1) WO2002094185A2 (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041859A2 (fr) 2003-04-30 2005-05-12 Sirna Therapeutics, Inc. Conjugues et compositions
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
CA2476468A1 (fr) * 2002-02-13 2003-08-21 Medbridge, Inc. Systeme de vecteur proteique pour des oligonucleotides therapeutiques
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8163896B1 (en) 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7655785B1 (en) 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7696334B1 (en) 2002-12-05 2010-04-13 Rosetta Genomics, Ltd. Bioinformatically detectable human herpesvirus 5 regulatory gene
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
US20040167090A1 (en) * 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
JP4597976B2 (ja) 2003-04-17 2010-12-15 アルナイラム ファーマシューティカルズ インコーポレイテッド 修飾ｉＲＮＡ剤
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
AU2012202250B2 (en) * 2003-04-17 2015-06-18 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
EP1654066B1 (fr) 2003-07-31 2014-11-12 Handylab, Inc. Traitement d'echantillons contenant des particules
US7888497B2 (en) 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US20050136437A1 (en) * 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
EP1704228B1 (fr) 2004-01-16 2012-04-11 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immunokinases
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
CA2562151C (fr) * 2004-04-30 2016-09-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comportant une pyrimidine a modification c5
US8852862B2 (en) 2004-05-03 2014-10-07 Handylab, Inc. Method for processing polynucleotide-containing samples
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
WO2005111211A2 (fr) 2004-05-14 2005-11-24 Rosetta Genomics Ltd. Micro-arn et utilisations de ceux-ci
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7795419B2 (en) 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
US7943589B2 (en) 2005-06-03 2011-05-17 President And Fellows Of Harvard College siRNA microbicides for preventing and treating diseases
JP2009504803A (ja) 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒアゴニスト
EP1800695A1 (fr) * 2005-12-21 2007-06-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immuno-RNA conjugues
US10900066B2 (en) 2006-03-24 2021-01-26 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
DK2001990T3 (en) 2006-03-24 2016-10-03 Handylab Inc Integrated microfluidic sample processing system and method for its use
US7998708B2 (en) 2006-03-24 2011-08-16 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US11806718B2 (en) 2006-03-24 2023-11-07 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
CN101460178B (zh) * 2006-04-07 2016-12-07 艾德拉药物股份有限公司 用于tlr7和tlr8的稳定化的免疫调节性rna(simra)化合物
WO2008061165A2 (fr) 2006-11-14 2008-05-22 Handylab, Inc. Cartouche microfluidique et son procédé de fabrication
WO2008060604A2 (fr) 2006-11-14 2008-05-22 Handylab, Inc. Système microfluidique utilisé pour amplifier et détecter des polynucléotides en parallèle
ES2456964T3 (es) * 2007-02-07 2014-04-24 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
EP2604283A1 (fr) 2007-02-16 2013-06-19 KTB Tumorforschungsgesellschaft mbH Récepteur et promédicament ciblé antigène
CA2685127C (fr) 2007-04-23 2019-01-08 Alnylam Pharmaceuticals, Inc. Glycoconjugues d'agents d'interference arn
US9186677B2 (en) 2007-07-13 2015-11-17 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US8182763B2 (en) 2007-07-13 2012-05-22 Handylab, Inc. Rack for sample tubes and reagent holders
US8324372B2 (en) 2007-07-13 2012-12-04 Handylab, Inc. Polynucleotide capture materials, and methods of using same
US8105783B2 (en) 2007-07-13 2012-01-31 Handylab, Inc. Microfluidic cartridge
US8287820B2 (en) 2007-07-13 2012-10-16 Handylab, Inc. Automated pipetting apparatus having a combined liquid pump and pipette head system
CN102006890A (zh) 2007-12-04 2011-04-06 阿尔尼拉姆医药品有限公司 靶向脂质
CA2708171C (fr) 2007-12-04 2018-02-27 Alnylam Pharmaceuticals, Inc. Conjugues du folate
EP3604533A1 (fr) 2008-04-11 2020-02-05 Arbutus Biopharma Corporation Délivrance spécifique à un site d'acides nucléiques en combinant des ligands de ciblage avec des composants endosomolytiques
DK3252068T3 (da) 2009-10-12 2025-08-25 Larry J Smith Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
US20120035362A1 (en) * 2010-08-03 2012-02-09 Berry And Associates, Inc. Phosphoramidite derivatives of folic acid
WO2012027206A1 (fr) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. Agents à base d'arni à un seul brin contenant une séquence intercalaire interne ne correspondant pas à un acide nucléique
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
EP2697657B8 (fr) 2011-04-15 2017-08-16 Becton, Dickinson and Company Thermocycleur microfluidique en temps réel à balayage et procédés synchronisés de thermocyclage et de détection optique à balayage
EP2773892B1 (fr) 2011-11-04 2020-10-07 Handylab, Inc. Dispositif de préparation d'échantillons de polynucléotides
NZ630990A (en) 2012-03-16 2016-04-29 Merck Patent Gmbh Aminoacid lipids
NZ631034A (en) 2012-03-16 2016-06-24 Merck Patent Gmbh Targeting aminoacid lipids
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
CN102875610A (zh) * 2012-09-19 2013-01-16 淮海工学院 一种制备2-乙酰氨基-2-脱氧-3,4,6-三乙酰-β-D-氯代吡喃葡糖的方法
KR101392973B1 (ko) 2012-10-15 2014-05-09 (주)바이오니아 ｓｉＲＮＡ 접합체 및 그 제조방법
SG10201804331TA (en) 2012-11-15 2018-07-30 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
US20170327524A1 (en) 2014-10-10 2017-11-16 Hoffmann-La Roche, Inc. Galnac phosphoramidites, nucleic acid conjugates thereof and their use
SG11201703638XA (en) 2014-11-10 2017-06-29 Alnylam Pharmaceuticals Inc Hepatitis b virus (hbv) irna compositions and methods of use thereof
US10246709B2 (en) 2016-03-07 2019-04-02 Arrowhead Pharmaceuticals, Inc. Targeting ligands for therapeutic compounds
EP3442983A1 (fr) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Composés trityl-mono-galnac et leur utilisation
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
EP3484908A4 (fr) 2016-07-15 2020-04-08 AM Chemicals Llc Supports solides non nucléosides et blocs de construction de phosphoramidite pour synthèse d'oligonucléotides
JP6989521B2 (ja) 2016-09-02 2022-01-05 アローヘッド ファーマシューティカルズ インコーポレイテッド 標的化リガンド
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
MA70658B1 (fr) 2018-08-13 2026-04-30 Alnylam Pharmaceuticals, Inc. Compositions d'agent d'arndb du virus de l'hépatite b (vhb) et leurs méthodes d'utilisation
EP3952919A2 (fr) * 2019-04-11 2022-02-16 Northeastern University Conjugués d'oligonucléotide-hétérobras polymères et procédés d'utilisation
CN110070506B (zh) * 2019-04-15 2022-07-19 武汉大学 一种基于多尺度混合指数模型的视频去雨方法
EP4114406A4 (fr) * 2019-11-21 2024-02-28 Gaziantep Universitesi Rektörlügu Synthèse et amélioration d'un analogue nucléosidique en tant que médicament anticancéreux et antiviral
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
AU2021309966A1 (en) 2020-07-15 2023-02-09 Biogen Ma Inc. Medical system including two access ports
JP7688152B2 (ja) 2021-04-16 2025-06-03 ギリアード サイエンシーズ， インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法
US12605537B2 (en) 2022-02-15 2026-04-21 Biogen Ma Inc. Implantable medical device for use with or having recording electrode
CN114767685B (zh) * 2022-04-25 2023-10-20 北京大学第三医院（北京大学第三临床医学院） 四氢叶酸在抑菌或者预防或治疗眼部疾病中的用途
WO2024240101A1 (fr) * 2023-05-24 2024-11-28 北京炫景瑞医药科技有限公司 Composé, conjugué, composition galnac et leur utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066063A2 (fr) * 1998-06-16 1999-12-23 Isis Pharmaceuticals, Inc. Conjugues de folates nucleosidiques et non nucleosidiques
WO2000044895A1 (fr) * 1999-01-30 2000-08-03 Roland Kreutzer Methode et medicament destines a inhiber l'expression d'un gene donne

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS1355B6 (is) * 1984-11-12 1989-04-19 Lister Institute Of Preventive Medicine Fjölkjarna kannar
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
CA1339303C (fr) 1987-09-21 1997-08-19 Lyle John Arnold Jr. Reactifs de liaison non nucleotidiques pour sondes nucleotidiques
CA1340323C (fr) 1988-09-20 1999-01-19 Arnold E. Hampel Catalyseur d'arn pour le clivage de sequences specifiques d'arn
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
AU637800B2 (en) 1989-08-31 1993-06-10 City Of Hope Chimeric dna-rna catalytic sequences
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
WO1992007065A1 (fr) 1990-10-12 1992-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Ribozymes modifies
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
WO1993023569A1 (fr) 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Procede et reactif d'inhibition de la replication virale
WO1994013791A1 (fr) 1992-12-04 1994-06-23 Innovir Laboratories, Inc. Acide nucleique regulable a usage therapeutique et procedes d'utilisation associes
JP3595841B2 (ja) 1992-12-04 2004-12-02 サーナ セラピューティクス，インコーポレイテッド リボザイム増幅診断用薬
US6046175A (en) * 1993-05-21 2000-04-04 The United States Of America As Represented By The Department Of Health And Human Services Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
US5871914A (en) 1993-06-03 1999-02-16 Intelligene Ltd. Method for detecting a nucleic acid involving the production of a triggering RNA and transcription amplification
WO1995006731A2 (fr) 1993-09-02 1995-03-09 Ribozyme Pharmaceuticals, Inc. Acide nucleique enzymatique contenant un non-nucleotide
US5861288A (en) 1993-10-18 1999-01-19 Ribozyme Pharmaceuticals, Inc. Catalytic DNA
ES2127948T3 (es) 1993-10-27 1999-05-01 Ribozyme Pharm Inc Oligonucleotidos modificados en la posicion 2'-amido y 2'-peptido.
US6093702A (en) * 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5633133A (en) 1994-07-14 1997-05-27 Long; David M. Ligation with hammerhead ribozymes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5716824A (en) 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
US5872241A (en) 1995-01-25 1999-02-16 The Trustees Of Columbia University In The City Of New York Multiple component RNA catalysts and uses thereof
DE19524515A1 (de) * 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
DE69637256T2 (de) 1996-01-16 2008-06-19 Sirna Therapeutics, Inc., Boulder Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
WO1998027104A1 (fr) 1996-12-19 1998-06-25 Yale University Polynucleotides allosteres bioreactifs
EP0948511B1 (fr) 1996-12-24 2006-10-18 Sirna Therapeutics, Inc. Synthese chimique d'analogues de nucleosides et leur incorporation dans des polynucleotides
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
WO1998043993A2 (fr) 1997-03-31 1998-10-08 Yale University Acides nucleiques en tant que catalyseurs
JP2002510207A (ja) 1997-06-19 2002-04-02 リボザイム・ファーマシューティカルズ・インコーポレーテッド 拡張された開裂ルールを有するハンマーヘッドリボザイム
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
JP2001518292A (ja) 1997-09-22 2001-10-16 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ エンドヌクレアーゼ活性を有する核酸触媒
AU9402198A (en) 1997-09-26 1999-04-23 Becton Dickinson & Company Preparing conjugates using polyethylene glycol linkers
JP2002506612A (ja) 1997-12-05 2002-03-05 デューク・ユニバーシティー 核酸仲介ｒｎａタグ付けおよびｒｎａ修復
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999054459A2 (fr) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Molecules d'acides nucleiques presentant de nouvelles compositions chimiques capables de moduler l'expression genique
JP2002512794A (ja) 1998-04-29 2002-05-08 リボザイム・ファーマシューティカルズ・インコーポレーテッド ヌクレオチド三リン酸およびリボザイム内へのそれらの取り込み
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
IL126731A0 (en) 1998-10-23 1999-08-17 Intelligene Ltd A method of detection
CA2348779A1 (fr) 1998-11-03 2000-05-11 Yale University Detecteurs moleculaires polynucleotidiques a domaines multiples
WO2000044914A1 (fr) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition et methode destinees a l'attenuation in vivo et in vitro de l'expression genique utilisant de l'arn double brin
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6020199A (en) * 1999-07-21 2000-02-01 Isis Pharmaceuticals Inc. Antisense modulation of PTEN expression
EP1235842A4 (fr) 1999-10-15 2003-04-23 Univ Massachusetts Genes de voies d'interference d'arn en tant qu'outils d'interference genetique ciblee
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
KR20040008526A (ko) 2002-07-18 2004-01-31 주식회사 하이닉스반도체 플래시 메모리 셀의 소거 방법
US8240498B2 (en) 2006-10-31 2012-08-14 Crown Packaging Technology, Inc. Resealable closure
US9301511B1 (en) 2015-05-05 2016-04-05 Harold Edward Clarambeau Fishing rig with floatation device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066063A2 (fr) * 1998-06-16 1999-12-23 Isis Pharmaceuticals, Inc. Conjugues de folates nucleosidiques et non nucleosidiques
WO2000044895A1 (fr) * 1999-01-30 2000-08-03 Roland Kreutzer Methode et medicament destines a inhiber l'expression d'un gene donne

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELBASHIR SAYDA M ET AL: "RNA interference is mediated by 21- and 22-nucleotide RNAs", GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, PLAINVIEW, NY, US, vol. 15, no. 2, 15 January 2001 (2001-01-15), pages 188 - 200, XP002204651, ISSN: 0890-9369 *
THOMAS MINI ET AL: "Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES SEP 2009 LNKD- PUBMED:19796075, vol. 1175, September 2009 (2009-09-01), pages 32 - 39, ISSN: 1749-6632 *

Also Published As

Publication number Publication date
JP2009149652A (ja) 2009-07-09
EP2415486B1 (fr) 2017-02-22
HK1244675A1 (en) 2018-08-17
AU2002316135B2 (en) 2009-01-08
AU2002316135B9 (en) 2009-05-28
AU2009200497A1 (en) 2009-02-26
WO2002094185A3 (fr) 2007-05-31
EP3231445A1 (fr) 2017-10-18
WO2002094185A2 (fr) 2002-11-28
EP2415486A2 (fr) 2012-02-08
EP1572067A2 (fr) 2005-09-14
EP2415486A3 (fr) 2013-01-09
JP4358521B2 (ja) 2009-11-04
JP2005505504A (ja) 2005-02-24
CA2447161A1 (fr) 2002-11-28

Similar Documents

Publication Publication Date Title
EP1622572A4 (fr) Conjugues et compositions pour la livraison cellulaire
AU2002339993A1 (en) P-amidobenzylethers in drug delivery agents
HUP0204137A3 (en) Pharmaceutical composition comprising fulvestrant
NO20020208L (no) Flytende sammensetninger for oral administrasjon
GB2358583B (en) Pharmaceutical compositions
HUP0300582A3 (en) Pharmaceutical compositions
HUP0203588A3 (en) Analgesic pharmaceutical compositions and their use
AU6219601A (en) Pharmaceutical compositions
AU2002335046A1 (en) The use of proton sequestering agents in drug formulations
GB0009584D0 (en) Pharmaceutical compositions
IL151910A0 (en) Compositions for drug delivery
AU2001232020A1 (en) Floating drug delivery composition
NO20020760D0 (no) Farmasöytiske sammensetninger for oral og topisk administrasjon
IS2841B (is) Samstæða hluta og lyfjasamsetningar
AU8576801A (en) Pharmaceutical compositions
AU1390002A (en) Pharmaceutical compositions
IL159006A0 (en) Phenoxy-phenyl derivatives and pharmaceutical compositions containing the same
GB0008485D0 (en) Pharmaceutical compositions
GB0009613D0 (en) Pharmaceutical compositions
AU2002308649A1 (en) Compositions and methods for enhancing drug delivery
EP1411897A4 (fr) Compositions et methodes d'administration intracellulaire
AU3926000A (en) Methods and compositions for drug delivery
AU2001262928A1 (en) Pharmaceutical compositions and their use
IT1318654B1 (it) Composizioni farmaceutiche comprendenti agenti antiinfiammatori e lorousi.
ZA200205556B (en) Pharmaceutical compositions and their preparation.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C08G 63/08 20060101ALI20090325BHEP

Ipc: A61K 9/14 20060101AFI20090325BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090417

RIC1 Information provided on ipc code assigned before grant

Ipc: C08G 63/08 20060101ALI20090409BHEP

Ipc: A61K 9/14 20060101ALI20090409BHEP

Ipc: A61K 47/48 20060101AFI20090409BHEP

17Q First examination report despatched

Effective date: 20090930

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20111220